To the Editor:

We would like to thank Chowdhary et al for their constructive comments[@bib1] regarding our recent publication describing mortality rates in a cohort of patients with coronavirus disease 2019 (COVID-19) with a history of radiotherapy.[@bib2] We wholeheartedly agree that additional potential risk factors, including comorbid medical conditions,[@bib3] should be included in future analyses on this topic. We are currently sharing patient data with large national and international consortia[@bib4]^,^[@bib5] to enable more definitive analyses.

To try to address other concerns about our analysis, we now present updated data. Additional deaths have unfortunately occurred in our cohort of 107 patients, including deaths more than 14 days after COVID-19 diagnosis. The actuarial 14-day survival rate is now 75%, and the 45-day survival rate is now 61%. [Figure 1](#fig1){ref-type="fig"} depicts the relationship between primary cancer type, mean lung radiation therapy dose, and vital status in our data set. [Figure 2](#fig2){ref-type="fig"} contains updated Kaplan-Meier survival curves.Figure 1Scatter plot depicting primary cancer diagnosis, mean lung radiation therapy dose, and vital status for patients who contracted coronavirus disease 2019 (COVID-19).Figure 2Updated Kaplan-Meier overall survival curves for patients grouped by mean lung radiation therapy dose.

We invite readers to make their own interpretations of our data. We find it plausible that patients with a history of significant lung irradiation may be at increased risk for complications when faced with a serious viral pneumonia. Until more conclusive data are available, we hope that all patients with thoracic cancers/tumors receive appropriate guidance and social support to minimize their risk of contracting COVID-19.
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